ALLMedicine™ Dry Skin Center
Research & Reviews 548 results
https://clinicaltrials.gov/ct2/show/NCT03742414
Jun 24th, 2022 - This is a randomized, controlled, parallel design, open-label phase 2 clinical study to compare the efficacy of the two proactive treatment arms versus the reactive arm, for the prevention of atopic dermatitis in children at high risk of food alle...
https://clinicaltrials.gov/ct2/show/NCT03434418
Jun 23rd, 2022 - This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20...
https://doi.org/10.1111/all.15418
Allergy Sindher SB, Long A et. al.
Jun 23rd, 2022 - The incidence of food allergy (FA) has continued to rise over the last several decades, posing significant burdens on health and quality of life. Significant strides into the advancement of FA diagnosis, prevention, and treatment have been made in...
https://doi.org/10.1093/neuonc/noac155
Neuro-oncology Natsume A, Arakawa Y et. al.
Jun 21st, 2022 - Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expa...
https://doi.org/10.1186/s12887-022-03382-3 10.1016/j.jaci.2015.11.029 10.1136/adc.2003.034033 10.1056/NEJMra2023911 10.1007/s40257-018-0383-4 10.1007/978-3-319-64804-0_8 10.1016/j.anai.2018.07.006 10.1111/j.1365-2133.2006.07185.x 10.1152/physrev.00032.2012 10.1016/0028-2243(86)90006-7 10.1016/0165-3806(83)90184-0 10.1016/j.mehy.2004.01.014 10.1038/77702 10.1111/jcpp.13085 10.1016/j.earlhumdev.2004.07.005 10.1111/j.1365-2230.2008.02853.x 10.1001/archpedi.159.8.745 10.1016/j.smrv.2010.01.004 10.1111/j.1399-3038.2006.00502.x 10.1097/DER.0000000000000161 10.12932/AP0772 10.5021/ad.2016.28.3.321 10.1111/j.1742-1241.2006.01047.x 10.3390/ijms17040462 10.1016/j.jaci.2018.08.005 10.1016/j.jaci.2015.08.028 10.1001/archpedi.153.3.249 10.1093/jpepsy/jsw016 10.1001/jamadermatol.2018.5641 10.1016/j.sleep.2017.04.015 10.1111/jsr.12414 10.1111/j.1365-2869.2009.00814.x 10.3390/brainsci5040494 10.1037/dev0000233 10.1136/jech.2009.093534 10.1056/NEJMra1011040 10.1111/pde.12106 10.1016/j.anai.2020.01.022 10.1038/jid.2008.280 10.1111/j.1398-9995.2010.02540.x 10.1001/jamadermatol.2019.2983 10.1111/bjd.17088 10.1016/0165-1781(89)90047-4 10.1111/bjd.15641 10.1016/j.clindermatol.2018.05.012 10.1111/all.12942 10.1016/j.jid.2016.06.633 10.1046/j.1365-2133.2001.03960.x 10.1111/bjd.12232 10.1111/1469-7610.00076
BMC Pediatrics; O'Connor C, Irvine AD et. al.
Jun 19th, 2022 - Atopic dermatitis (AD) is the most common chronic inflammatory skin condition in childhood. Most (50-60%) children with AD report sleep disturbance, which is secondary to itch, dry skin, inflammation, and abnormal circadian rhythm. Sleep is essent...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717
Drugs Califano R, Tariq N et. al.
Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...
Drugs 287 results see all →
Clinicaltrials.gov 64 results
https://clinicaltrials.gov/ct2/show/NCT03742414
Jun 24th, 2022 - This is a randomized, controlled, parallel design, open-label phase 2 clinical study to compare the efficacy of the two proactive treatment arms versus the reactive arm, for the prevention of atopic dermatitis in children at high risk of food alle...
https://clinicaltrials.gov/ct2/show/NCT03434418
Jun 23rd, 2022 - This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20...
https://clinicaltrials.gov/ct2/show/NCT05368116
May 20th, 2022 - Effectiveness A measure of the extent to which a specific intervention, procedure, regimen, or service when deployed in the field of routine circumstances, does it intended to do for a specific population. (Wojtezak, 2002) In this study, effective...
https://clinicaltrials.gov/ct2/show/NCT04594759
May 9th, 2022 - In current Dermatology practice, options for moderate acne vulgaris remain limited. Moderate acne is clinically defined as acne that has not responded to at least three months of topical therapy and is not severe enough for initial treatment with ...
https://clinicaltrials.gov/ct2/show/NCT05013645
Apr 27th, 2022 - Double-blind placebo-controlled clinical trial to evaluate the effectiveness of a sterilized probiotic on skin health and hydration in adults with dry skin. The goal of the study is to determine if the addition of a skin-conditioning probiotic to ...
News 184 results
https://www.mdedge.com/familymedicine/article/254757/dermatology/itching-night
MDedge Family Medicine;
May 19th, 2022 - Microscopic evaluation of a dermoscopy-guided skin scraping revealed that this was a case of scabies. Classically, patients with scabies have many excoriated papules or plaques on their hands, genitals, and trunk with itching so intense that their.
https://www.mdedge.com/dermatology/article/252370/atopic-dermatitis/update-jak-inhibitors-skin-disease
Alexandra Norden, BA, Aislyn Oulee, BS et. al.
Mar 3rd, 2022 - Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting 7% of adults and 13% of children in the United States. 1,2 Atopic dermatitis is characterized by pruritus, dry skin, and pain, all of which can negatively impact quality of li.
https://www.medpagetoday.com/hematologyoncology/hematology/96918
Jan 28th, 2022 - Patients with relapsed or corticosteroid-resistant immune thrombocytopenia (ITP) had a 33% higher response rate and 50% increase in sustained responses with all-trans retinoic acid (ATRA) plus low-dose rituximab (Rituxan), Chinese investigators re...
https://www.onclive.com/view/adagrasib-with-or-without-cetuximab-produces-encouraging-clinical-activity-in-kras-g12c-mutant-crc
Jan 13th, 2022 - Adagrasib (MRTX849), both alone and in combination with cetuximab (Erbitux), demonstrated encouraging responses and disease control in heavily pretreated patients with KRAS G12C–mutated colorectal cancer (CRC), according to Jared Weiss, MD, who ad...
https://www.onclive.com/view/mobocertinib-provides-treatment-option-for-egfr-exon-20-mutant-nsclc
Nov 19th, 2021 - Mobocertinib (Exkivity), a first-in-class oral EGFR tyrosine kinase inhibitor (TKI), has been granted accelerated approval by the FDA, establishing a new treatment option for patients with metastatic non–small cell lung cancer (NSCLC) that harbors...
